1
|
Roy S, Levi E, Majumdar AP and Sarkar FH:
Expression of miR-34 is lost in colon cancer which can be
re-expressed by a novel agent CDF. J Hematol Oncol. 5:582012.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Lodygin D, Tarasov V, Epanchintsev A,
Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J and Hermeking
H: Inactivation of miR-34a by aberrant CpG methylation in multiple
types of cancer. Cell Cycle. 7:2591–2600. 2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
The Korea National Statistical Office
Report 2015, . Change in leading causes of death (2000–2015). Korea
National Statistical Office. http://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B34E13&vw_cd=MT_ZTITLE&list_id=D11&seqNo=&lang_mode=ko&language=kor&obj_var_id=&itm_id=&conn_path=MT_ZTITLEJanuary
26–2018
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Park Y, Lee J, Oh JH, Shin A and Kim J:
Dietary patterns and colorectal cancer risk in a Korean population:
A case-control study. Medicine (Baltimore). 95:e37592016.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Gallardo E, Navarro A, Viñolas N, Marrades
RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez
J and Monzo M: miR-34a as a prognostic marker of relapse in
surgically resected non-small-cell lung cancer. Carcinogenesis.
30:1903–1909. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Tarasov V, Jung P, Verdoodt B, Lodygin D,
Epanchintsev A, Menssen A, Meister G and Hermeking H: Differential
regulation of microRNAs by p53 revealed by massively parallel
sequencing: miR-34a is a p53 target that induces apoptosis and
G1-arrest. Cell Cycle. 6:1586–1593. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Zamore PD and Haley B: Ribo-gnome: The big
world of small RNAs. Science. 309:1519–1524. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Hutvágner G, McLachlan J, Pasquinelli AE,
Bálint E, Tuschl T and Zamore PD: A cellular function for the
RNA-interference enzyme Dicer in the maturation of the let-7 small
temporal RNA. Science. 293:834–838. 2001. View Article : Google Scholar : PubMed/NCBI
|
10
|
Lund E, Güttinger S, Calado A, Dahlberg JE
and Kutay U: Nuclear export of microRNA precursors. Science.
303:95–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Davalos V and Esteller M: MicroRNAs and
cancer epigenetics: A macrorevolution. Curr Opin Oncol. 22:35–45.
2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ahmad A, Zhang W, Wu M, Tan S and Zhu T:
Tumor-suppressive miRNA-135a inhibits breast cancer cell
proliferation by targeting ELK1 and ELK3 oncogenes. Genes Genomics.
40:243–251. 2018. View Article : Google Scholar : PubMed/NCBI
|
14
|
Bommer GT, Gerin I, Feng Y, Kaczorowski
AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al:
p53-mediated activation of miRNA34 candidate tumor-suppressor
genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
|
15
|
He L, He X, Lim LP, de Stanchina E, Xuan
Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
He X, He L and Hannon GJ: The guardian's
little helper: microRNAs in the p53 tumor suppressor network.
Cancer Res. 67:11099–11101. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Bagchi A, Papazoglu C, Wu Y, Capurso D,
Brodt M, Francis D, Bredel M, Vogel H and Mills AA: CHD5 is a tumor
suppressor at human 1p36. Cell. 128:459–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chang TC, Wentzel EA, Kent OA,
Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M,
Ferlito M, Lowenstein CJ, et al: Transactivation of miR-34a by p53
broadly influences gene expression and promotes apoptosis. Mol
Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Mori N, Morosetti R, Spira S, Lee S,
Ben-Yehuda D, Schiller G, Landolfi R, Mizoguchi H and Koeffler HP:
Chromosome band 1p36 contains a putative tumor suppressor gene
important in the evolution of chronic myelocytic leukemia. Blood.
92:3405–3409. 1998.PubMed/NCBI
|
20
|
Welch C, Chen Y and Stallings RL:
MicroRNA-34a functions as a potential tumor suppressor by inducing
apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Hrašovec S and Glavač D: MicroRNAs as
novel biomarkers in colorectal cancer. Front Genet. 3:1802012.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Cho SH, Ko JJ, Kim JO, Jeon YJ, Yoo JK, Oh
J, Oh D, Kim JW and Kim NK: 3′-UTR polymorphisms in the miRNA
machinery genes DROSHA, DICER1, RAN, and XPO5 are associated with
colorectal cancer risk in a Korean population. PLoS One.
10:e01311252015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Toyota M, Suzuki H, Sasaki Y, Maruyama R,
Imai K, Shinomura Y and Tokino T: Epigenetic silencing of
microRNA-34b/c and B-cell translocation gene 4 is associated with
CpG island methylation in colorectal cancer. Cancer Res.
68:4123–4132. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kozaki K, Imoto I, Mogi S, Omura K and
Inazawa J: Exploration of tumor-suppressive microRNAs silenced by
DNA hypermethylation in oral cancer. Cancer Res. 68:2094–2105.
2008. View Article : Google Scholar : PubMed/NCBI
|
25
|
Lujambio A, Calin GA, Villanueva A, Ropero
S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso
MS, Faller WJ, et al: A microRNA DNA methylation signature for
human cancer metastasis. Proc Natl Acad Sci USA. 105:13556–13561.
2008. View Article : Google Scholar : PubMed/NCBI
|
26
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Ooncol.
13:e249–e258. 2012. View Article : Google Scholar
|
27
|
Lujambio A, Ropero S, Ballestar E, Fraga
MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A,
Sanchez-Cespedes M, Git A, et al: Genetic unmasking of an
epigenetically silenced microRNA in human cancer cells. Cancer Res.
67:1424–1429. 2007. View Article : Google Scholar : PubMed/NCBI
|
28
|
Iwai N and Naraba H: Polymorphisms in
human pre-miRNAs. Biochem Biophys Res Commun. 331:1439–1444. 2005.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen
J, Liu S, Liu Z, Shi H, Shen H and Hu Z: A potentially functional
polymorphism in the promoter region of miR-34b/c is associated with
an increased risk for primary hepatocellular carcinoma. Int J
Cancer. 128:412–417. 2011. View Article : Google Scholar : PubMed/NCBI
|
30
|
Gao LB, Li LJ, Pan XM, Li ZH, Liang WB,
Bai P, Zhu YH and Zhang L: A genetic variant in the promoter region
of miR-34b/c is associated with a reduced risk of colorectal
cancer. Biol Chem. 394:415–420. 2013. View Article : Google Scholar : PubMed/NCBI
|
31
|
Hiroki E, Suzuki F, Akahira J, Nagase S,
Ito K, Sugawara J, Miki Y, Suzuki T, Sasano H and Yaegashi N:
MicroRNA-34b functions as a potential tumor suppressor in
endometrial serous adenocarcinoma. Int J Cancer. 131:E395–E404.
2012. View Article : Google Scholar : PubMed/NCBI
|
32
|
Bensen JT, Tse CK, Nyante SJ,
Barnholtz-Sloan JS, Cole SR and Millikan RC: Association of
germline microRNA SNPs in pre-miRNA flanking region and breast
cancer risk and survival: The carolina breast cancer study. Cancer
Causes Control. 24:1099–1109. 2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Dumont P, Leu JI, Della Pietra AC III,
George DL and Murphy M: The codon 72 polymorphic variants of p53
have markedly different apoptotic potential. Nat Genet. 33:357–365.
2003. View
Article : Google Scholar : PubMed/NCBI
|
34
|
Irarrázabal CE, Rojas C, Aracena R,
Márquez C and Gil L: Chilean pilot study on the risk of lung cancer
associated with codon 72 polymorphism in the gene of protein p53.
Toxicol Lett. 144:69–76. 2003. View Article : Google Scholar : PubMed/NCBI
|
35
|
Kuroda Y, Tsukino H, Nakao H, Imai H and
Katoh T: p53 codon 72 polymorphism and urothelial cancer risk.
Cancer Lett. 189:77–83. 2003. View Article : Google Scholar : PubMed/NCBI
|
36
|
Rokni P, Shariatpanahi AM, Sakhinia E and
Kerachian MA: BMP3 promoter hypermethylation in plasma-derived
cell-free DNA in colorectal cancer patients. Genes Genomics.
40:423–428. 2018. View Article : Google Scholar : PubMed/NCBI
|
37
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
38
|
Vogt M, Munding J, Grüner M, Liffers ST,
Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A and Hermeking H:
Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG
methylation in colorectal, pancreatic, mammary, ovarian,
urothelial, and renal cell carcinomas and soft tissue sarcomas.
Virchows Arch. 458:313–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
39
|
Eads CA, Danenberg KD, Kawakami K, Saltz
LB, Blake C, Shibata D, Danenberg PV and Laird PW: MethyLight: A
high-throughput assay to measure DNA methylation. Nucleic Acids
Res. 28:E322000. View Article : Google Scholar : PubMed/NCBI
|
40
|
Cottrell S, Jung K, Kristiansen G, Eltze
E, Semjonow A, Ittmann M, Hartmann A, Stamey T, Haefliger C and
Weiss G: Discovery and validation of 3 novel DNA methylation
markers of prostate cancer prognosis. J Urol. 177:1753–1758. 2007.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Deng G, Kakar S and Kim YS: MicroRNA-124a
and microRNA-34b/c are frequently methylated in all histological
types of colorectal cancer and polyps, and in the adjacent normal
mucosa. Oncol Lett. 2:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
|
42
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
|
44
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
45
|
Rinaldi A, Poretti G, Kwee I, Zucca E,
Catapano CV, Tibiletti MG and Bertoni F: Concomitant MYC and
microRNA cluster miR-17-92 (C13orf25) amplification in human mantle
cell lymphoma. Leuk Lymphoma. 48:410–412. 2007. View Article : Google Scholar : PubMed/NCBI
|
46
|
Wang Z, Chen Z, Gao Y, Li N, Li B, Tan F,
Tan X, Lu N, Sun Y, Sun J, et al: DNA hypermethylation of
microRNA-34b/c has prognostic value for stage I non-small cell lung
cancer. Cancer Biol Ther. 11:490–496. 2011. View Article : Google Scholar : PubMed/NCBI
|
47
|
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y and
Zheng X: miR-34a inhibits migration and invasion by down-regulation
of c-Met expression in human hepatocellular carcinoma cells. Cancer
Lett. 275:44–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
48
|
Tazawa H, Tsuchiya N, Izumiya M and
Nakagama H: Tumor-suppressive miR-34a induces senescence-like
growth arrest through modulation of the E2F pathway in human colon
cancer cells. Proc Natl Acad Sci USA. 104:15472–15477. 2007.
View Article : Google Scholar : PubMed/NCBI
|
49
|
Yan D, Zhou X, Chen X, Hu DN, Dong XD,
Wang J, Lu F, Tu L and Qu J: MicroRNA-34a inhibits uveal melanoma
cell proliferation and migration through downregulation of c-Met.
Invest Ophthalmol Vis Sci. 50:1559–1565. 2009. View Article : Google Scholar : PubMed/NCBI
|
50
|
Rokavec M, Li H, Jiang L and Hermeking H:
The p53/miR-34 axis in development and disease. J Mol Cell Biol.
6:214–230. 2014. View Article : Google Scholar : PubMed/NCBI
|
51
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
52
|
Roman-Gomez J, Agirre X, Jiménez-Velasco
A, Arqueros V, Vilas-Zornoza A, Rodriguez-Otero P, Martin-Subero I,
Garate L, Cordeu L, San José-Eneriz E, et al: Epigenetic regulation
of microRNAs in acute lymphoblastic leukemia. J Clin Oncol.
27:1316–1322. 2009. View Article : Google Scholar : PubMed/NCBI
|
53
|
Oh J, Kim JW, Lee BE, Jang MJ, Chong SY,
Park PW, Hwang SG, Oh D and Kim NK: Polymorphisms of the
pri-miR-34b/c promoter and TP53 codon 72 are associated with risk
of colorectal cancer. Oncol Rep. 31:995–1002. 2014. View Article : Google Scholar : PubMed/NCBI
|
54
|
Itahana Y and Itahana K: Emerging roles of
p53 family members in glucose metabolism. Int J Mol Sci. 19(pii):
E7762018. View Article : Google Scholar : PubMed/NCBI
|
55
|
Gnanapradeepan K, Basu S, Barnoud T,
Budina-Kolomets A, Kung CP and Murphy ME: The p53 tumor suppressor
in the control of metabolism and ferroptosis. Front Endocrinol
(Lausanne). 9:1242018. View Article : Google Scholar : PubMed/NCBI
|
56
|
Vousden KH: Functions of p53 in metabolism
and invasion. Biochem Soc Trans. 37:511–517. 2009. View Article : Google Scholar : PubMed/NCBI
|
57
|
Bellini I, Pitto L, Marini MG, Porcu L,
Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi
M, et al: DeltaN133p53 expression levels in relation to haplotypes
of the TP53 internal promoter region. Hum Mutat. 31:456–465. 2010.
View Article : Google Scholar : PubMed/NCBI
|